Augusta SPH wins $50,000 PACELINE grant, raising a UAE oncology follow-up question

Augusta University School of Public Health has secured a $50,000 PACELINE grant to study cancer survivorship barriers in rural Georgia, a modest US award with a direct question for UAE oncology operators: who owns the patient after active treatment ends?

The story matters most for UAE COOs, medical directors and insurers. Follow-up oncology care depends on scheduled scans, genetic evaluation where indicated, medication adherence, navigation and payer approval. In Dubai, that pathway sits under Dubai Health Authority (DHA) licensing and claims rules. In Abu Dhabi and Al Ain, it sits under the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, Ministry of Health and Prevention (MOHAP) licensing applies.

What the Georgia study will test

The Jagwire report, published on 10 September 2026, said the grant will fund qualitative data collection in Greensboro, Greene County, Georgia. The study period runs from July 2026 to June 2027. Researchers chose the area because it is rural and sits roughly halfway between Augusta and Atlanta, forcing many cancer survivors to travel for specialist oncology care.

Sejong Bae, PhD, professor and chair of the Department of Biostatistics, Data Science, and Epidemiology, is contact principal investigator. Steven Coughlin, PhD, professor and programme director, and Marlo Vernon, PhD, associate professor in health management, economics and policy, are multiple principal investigators. The work focuses on breast, colorectal, prostate and lung cancer, four high-volume tumour groups where surveillance failures can become clinical and financial events.

“The procedure was very successful and I am very happy to have it over with,” Steven Coughlin, PhD, told Jagwire.

Coughlin’s role is unusual because he is also a patient. Jagwire reported that he was diagnosed in June 2026 with stage 1 hepatocellular carcinoma after an elevated alpha-fetoprotein test led to MRI review. He received Y90 embolisation on 26 August 2026 and expects follow-up MRI scans every four months.

Why UAE clinics and insurers should care

The UAE issue is less about rural distance and more about handoff discipline. A Dubai oncology patient may move between hospital oncology, imaging, laboratory genetics, primary care, home nursing and insurer pre-authorisation within one episode. Each handoff has an operational owner. When that owner is unclear, missed MRI bookings and delayed authorisations become avoidable risk.

For CFOs, the practical number is the approved tariff, not the public shelf price. UAE providers should check their own network contracts and eClaim mappings for surveillance MRI, PET-CT, tumour markers, genetic counselling and oncology consultation codes. For Abu Dhabi lives, finance teams should verify Daman and Thiqa approval rules directly in contract schedules and DOH-linked claims guidance. For Dubai and multi-emirate private lives, they should check Sukoon and other payer portals before quoting patients.

• COOs should map survivorship follow-up by tumour group, scan interval and named staff owner.
• Medical directors should define when genetic evaluation is indicated after breast, colorectal or prostate cancer.
• CIOs should build recall lists that flag missed imaging and expired insurer approvals.
• Insurers should test whether pre-authorisation rules delay surveillance inside recommended follow-up windows.

Eligibility must also be explicit. The Augusta study asks patients and providers what barriers they face and how patient navigation could work. UAE clinics can run the same audit without waiting for a grant: select one tumour group, review all patients who completed active treatment in the past 12 months, then measure how many have a documented surveillance plan, next appointment date and payer approval status.

What to do next in the UAE

DHA-licensed providers in Dubai should start with oncology and radiology appointment leakage, because the patient can remain clinically attached to the provider while missing the scan that proves remission. DOH-regulated providers in Abu Dhabi and Al Ain should add payer approval timing, given the role of Daman and Thiqa in many patient flows. MOHAP-regulated providers in the northern emirates should check whether patients are being referred out for oncology subspecialty care without a closed-loop follow-up note.

The Augusta team plans to use the PACELINE data to support a larger National Institutes of Health R01 grant proposal. UAE operators should treat the story as a survivorship operations case study. The next competitive advantage in oncology may be the clinic that can prove patients complete scans, receive genetic counselling when eligible and know who to call between visits.

Patients and referring physicians can use the UAE Open Healthcare Directory to identify licensed oncology providers in Dubai, Abu Dhabi and the northern emirates before booking or referring care.